Bioasis Technologies (FRA:107) FCF Margin % : -296.33% (As of Nov. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Bioasis Technologies FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bioasis Technologies's Free Cash Flow for the three months ended in Nov. 2022 was €-0.32 Mil. Bioasis Technologies's Revenue for the three months ended in Nov. 2022 was €0.11 Mil. Therefore, Bioasis Technologies's FCF Margin % for the quarter that ended in Nov. 2022 was -296.33%.

As of today, Bioasis Technologies's current FCF Yield % is 0.00%.

The historical rank and industry rank for Bioasis Technologies's FCF Margin % or its related term are showing as below:

FRA:107' s FCF Margin % Range Over the Past 10 Years
Min: -696.02 Med: 0 Max: 0
Current: -696.02

FRA:107's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -144.01 vs FRA:107: -696.02

Bioasis Technologies FCF Margin % Historical Data

The historical data trend for Bioasis Technologies's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies FCF Margin % Chart

Bioasis Technologies Annual Data

Trend

Feb13

Feb14

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

FCF Margin %

Get a 7-Day Free Trial

-640.00

-227.32

-544.74

43.45

-9,692.31

Bioasis Technologies Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
FCF Margin %	Get a 7-Day Free Trial															-2,534.62	-	-	-185.87	-296.33

Competitive Comparison of Bioasis Technologies's FCF Margin %

For the Biotechnology subindustry, Bioasis Technologies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioasis Technologies's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's FCF Margin % falls into.

Bioasis Technologies FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Bioasis Technologies's FCF Margin for the fiscal year that ended in Feb. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Feb. 2022 )	/	Revenue (A: Feb. 2022 )
	=	-2.52	/	0.026
	=	-9,692.31 %

Bioasis Technologies's FCF Margin for the quarter that ended in Nov. 2022 is calculated as

FCF Margin	=	Free Cash Flow (Q: Nov. 2022 )	/	Revenue (Q: Nov. 2022 )
	=	-0.323	/	0.109
	=	-296.33 %

Bioasis Technologies FCF Margin % Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioasis Technologies (FRA:107) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (FRA:107) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

157 Church Street, 19th Floor, New Haven, CT, USA, 06510

Website

https://www.bioasis.us

Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies (FRA:107) Headlines

No Headlines